CoChat
Sign Up
Cited by 75

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Central Resistin Induces Hepatic Insulin Resistance via Neuropeptide Y

Singhal, Neel S., Lazar, Mitchell A., Ahima, Rexford S.·2007·The Journal of Neuroscience
DOI 10.1523/jneurosci.2443-07.2007
Open this paper in CoChat — free account

Abstract

Sensing of peripheral hormones and nutrients by the hypothalamus plays an important role in maintaining peripheral glucose homeostasis. The hormone resistin impairs the response to insulin in liver and other peripheral tissues. Here we demonstrate that in normal mice resistin delivered in the lateral cerebral ventricle increased endogenous glucose production during hyperinsulinemic-euglycemic clamp, consistent with induction of hepatic insulin resistance. In agreement, central resistin inhibited Akt phosphorylation and increased the expression of glucose-6-phosphatase, the enzyme regulating glucose output in the liver. Central resistin induced expression of proinflammatory cytokines as well as suppressor of cytokine signaling-3, a negative regulator of insulin action in liver. Central infusion of resistin was associated with neuronal activation in the arcuate, paraventricular and dorsomedial nuclei, and increased neuropeptide Y (NPY) expression in the hypothalamus. The effects of central resistin on glucose production as well as hepatic expression of proinflammatory cytokines were abrogated in mice lacking NPY. Pretreatment of wild-type mice with antagonists of the NPY Y1 receptor, but not the Y5 receptor, also prevented the effects of central resistin. Together, these results suggest that resistin action on NPY neurons is an important regulator of hepatic insulin sensitivity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.2443-07.2007

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
CC-BY-NC-SA · From the PDF
Figure 2 Central resistin stimulates Fos immunoreactivity (ir) specifically in hypothalamic regions. A , Photomicrographs of coronal brain sections showing Fos immunostaining in the arcuate (Arc), paraventricular (PVN), and dorsomedial nucleus (DMN), after intracerebroventricular resistin (white bars) or vehicle (black bars) treatment. B , C , Number of Fos-ir cells per section in hypothalamic ( B ) and extrahypothalamic ( C ) regions. Data are mean Fos-ir cells/hemisphere ± SEM, n = 4. * p < 0.05; ** p < 0.001versusvehicle.3v,Thirdventricle;me,medianeminence;SCN,suprachiasmaticnucleus,MPO,medialpreopticnucleus,LHA, lateral hypothalamic area; VMH, ventromedial hypothalamus; AHA, anterior hypothalamic area; PeV, periventricular nucleus; Ctx, cortex (primary motor); BLA, basolateral amygdala; BSTL, lateral bed nucleus of the stria terminalis; DMX, dorsal vagal nucleus; LC, locus ceruleus; NTS, nucleus tractus solitarius; PB, parabrachial nucleus; Rt, reticular thalamus. Scale bar, 250 𝛍 m.
Figure 2 Central resistin stimulates Fos immunoreactivity (ir) specifically in hypothalamic regions. A , Photomicrographs of coronal brain sections showing Fos immunostaining in the arcuate (Arc), paraventricular (PVN), and dorsomedial nucleus (DMN), after intracerebroventricular resistin (white bars) or vehicle (black bars) treatment. B , C , Number of Fos-ir cells per section in hypothalamic ( B ) and extrahypothalamic ( C ) regions. Data are mean Fos-ir cells/hemisphere ± SEM, n = 4. * p < 0.05; ** p < 0.001versusvehicle.3v,Thirdventricle;me,medianeminence;SCN,suprachiasmaticnucleus,MPO,medialpreopticnucleus,LHA, lateral hypothalamic area; VMH, ventromedial hypothalamus; AHA, anterior hypothalamic area; PeV, periventricular nucleus; Ctx, cortex (primary motor); BLA, basolateral amygdala; BSTL, lateral bed nucleus of the stria terminalis; DMX, dorsal vagal nucleus; LC, locus ceruleus; NTS, nucleus tractus solitarius; PB, parabrachial nucleus; Rt, reticular thalamus. Scale bar, 250 𝛍 m.CC-BY-NC-SA · From the PDF
Figure 3 Central resistin increases NPY expression in the hypothalamus. A , Effect of intracerebroventricular resistin (white bar) versus vehicle (black bar) on neuropeptide mRNA levels in the hypothalamus. Data are mean ± SEM, n = 6-8. * p < 0.05. B , Darkfield photomicrographs of coronal sections of the hypothalamus showing NPY mRNA expression in the Arc and dorsomedial nucleus (DMN). Scale bars: Arc, 200 𝛍 m; DMN, 100 𝛍 m. C , Intensity of signal was quantified using NIH Image J. Data are mean ± SEM, n = 4/group. * p < 0.05; ** p < 0.01 versus vehicle. D , Brightfield photomicrographs showing colocalization of For-ir (brown nuclear stain) and silver grains corresponding to NPY mRNA in Arc and DMN. Scale bars, 50 𝛍 m. Red arrow depicts a Fos-ir neuron, black arrow depicts a double-labeled neuron, and green arrow depicts a neuron expressing only NPY mRNA.
Figure 3 Central resistin increases NPY expression in the hypothalamus. A , Effect of intracerebroventricular resistin (white bar) versus vehicle (black bar) on neuropeptide mRNA levels in the hypothalamus. Data are mean ± SEM, n = 6-8. * p < 0.05. B , Darkfield photomicrographs of coronal sections of the hypothalamus showing NPY mRNA expression in the Arc and dorsomedial nucleus (DMN). Scale bars: Arc, 200 𝛍 m; DMN, 100 𝛍 m. C , Intensity of signal was quantified using NIH Image J. Data are mean ± SEM, n = 4/group. * p < 0.05; ** p < 0.01 versus vehicle. D , Brightfield photomicrographs showing colocalization of For-ir (brown nuclear stain) and silver grains corresponding to NPY mRNA in Arc and DMN. Scale bars, 50 𝛍 m. Red arrow depicts a Fos-ir neuron, black arrow depicts a double-labeled neuron, and green arrow depicts a neuron expressing only NPY mRNA.CC-BY-NC-SA · From the PDF
Figure 4 NPY mediates induction of hepatic insulin resistance by resistin. A , Hyperinsulinemic-euglycemic clamp in npy -/ -mice treated with intracerebroventricular resistin (white bars) or vehicle (black bars). B , Effects of intracerebroventricular resistin on protein. C , mRNA expression of mediators of insulin signaling in the liver during hyperinsulinemic-euglycemic clamp. Data are means ± SEM, n = 7-8/group.
Figure 4 NPY mediates induction of hepatic insulin resistance by resistin. A , Hyperinsulinemic-euglycemic clamp in npy -/ -mice treated with intracerebroventricular resistin (white bars) or vehicle (black bars). B , Effects of intracerebroventricular resistin on protein. C , mRNA expression of mediators of insulin signaling in the liver during hyperinsulinemic-euglycemic clamp. Data are means ± SEM, n = 7-8/group.CC-BY-NC-SA · From the PDF
Figure 5 Pharmacological blockade of NPY Y1 receptors, but not of Y5 receptors, prevents the induction of hepatic insulin resistance by resistin. A , B , Hyperinsulinemic-euglycemic clamp andhepatic protein levels in wild-type mice treated with intracerebroventricular NPY Y1 receptor antagonist, BIBP3226, or vehicle followed by intracerebroventricular resistin (white bars) or vehicle (hatched bars), n = 6/group. C , D , Hyperinsulinemic-euglycemic clamp and hepatic protein levels in wild-type mice treated with intracerebroventricular NPY Y5 receptor antagonist, CGP71683 or vehicle followed by intracerebroventricular resistin (white bars) or vehicle (hatched bars), n = 4/group. Data are means ± SEM * p < 0.05 versus vehicle/vehicle (black bars); ** p < 0.01 versus vehicle/vehicle; 𝛅 p < 0.05 versus antagonist/vehicle.
Figure 5 Pharmacological blockade of NPY Y1 receptors, but not of Y5 receptors, prevents the induction of hepatic insulin resistance by resistin. A , B , Hyperinsulinemic-euglycemic clamp andhepatic protein levels in wild-type mice treated with intracerebroventricular NPY Y1 receptor antagonist, BIBP3226, or vehicle followed by intracerebroventricular resistin (white bars) or vehicle (hatched bars), n = 6/group. C , D , Hyperinsulinemic-euglycemic clamp and hepatic protein levels in wild-type mice treated with intracerebroventricular NPY Y5 receptor antagonist, CGP71683 or vehicle followed by intracerebroventricular resistin (white bars) or vehicle (hatched bars), n = 4/group. Data are means ± SEM * p < 0.05 versus vehicle/vehicle (black bars); ** p < 0.01 versus vehicle/vehicle; 𝛅 p < 0.05 versus antagonist/vehicle.CC-BY-NC-SA · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 39

  1. 10.1038/oby.2006.317 · DOI
  2. 10.1126/science.1092341 · DOI
  3. 10.1098/rstb.2006.1855 · DOI
  4. 10.1038/35013070 · DOI · Paper page
  5. 10.1172/JCI4188 · DOI
  6. 10.1016/0167-0115(96)00074-2 · DOI
  7. 10.1002/1096-9861(20000724)423:2<261::AID-CNE6>3.0.CO;2-6 · DOI
  8. 10.1073/pnas.95.2.741 · DOI
  9. 10.1172/JCI200316426 · DOI
  10. 10.1016/S0092-8674(03)01081-X · DOI
  11. 10.1097/00001756-199810260-00015 · DOI
  12. 10.1038/nature05485 · DOI · Paper page
  13. 10.1016/j.cmet.2006.02.009 · DOI
  14. 10.1016/j.cmet.2004.12.003 · DOI · Paper page
  15. 10.1523/JNEUROSCI.5328-03.2004 · DOI · Paper page
  16. 10.1016/j.cmet.2006.06.010 · DOI
  17. 10.1210/jc.2006-1841 · DOI
  18. Lin EJ Sainsbury A Lee NJ Boey D Couzens M Enriquez R Slack K Bland R During MJ Herzog H (2006) Combined deletion of Y1, Y2 and Y4 receptors prevents hypothalamic NPY overexpression-induced hyperinsulinemia despite persistence of hyperphagia and obesity. Endocrinology. · DOI
  19. 10.1172/JCI27775 · DOI
  20. 10.1038/nature02440 · DOI · Paper page
  21. 10.1080/00365510601032532 · DOI
  22. 10.1172/JCI200421270 · DOI
  23. 10.1172/JCI30440 · DOI
  24. 10.1016/0168-0102(95)00965-V · DOI
  25. 10.2337/db05-0624 · DOI
  26. 10.1126/science.1093466 · DOI
  27. 10.1074/jbc.M304869200 · DOI
  28. 10.2337/db05-0615 · DOI
  29. 10.1172/JCI200316521 · DOI
  30. 10.2337/diabetes.53.7.1671 · DOI
  31. 10.2337/diabetes.53.8.1937 · DOI
  32. 10.1172/JCI200420785 · DOI
  33. 10.1126/science.1104344 · DOI · Paper page
  34. 10.2337/diabetes.55.03.06.db05-0841 · DOI
  35. 10.1128/MCB.25.4.1569-1575.2005 · DOI
  36. 10.1016/j.jhep.2004.05.006 · DOI
  37. 10.1210/en.139.11.4634 · DOI · Paper page
  38. 10.2337/diabetes.53.10.2529 · DOI · Paper page
  39. 10.1159/000084871 · DOI

Cited by

Sorted by citations

Metadata

Authors
Singhal, N. S., Lazar, M. A., & Ahima, R. S.
Venue
The Journal of Neuroscience
Publisher
Society for Neuroscience
Published
2007-11-21
Volume
27
Issue
47
Pages
12924-12932
ISSN
  • 0270-6474
  • 1529-2401
DOI
10.1523/jneurosci.2443-07.2007
Cited by
75
References
9
Language
en
Licence
creativecommons.org/licenses/by-nc-sa/4.0/ (vor, 182 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review